Axon Enterprise, Inc. (NASDAQ:AXON) CEO Patrick W. Smith Sells 70,000 Shares

Axon Enterprise, Inc. (NASDAQ:AXON) CEO Patrick W. Smith sold 70,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $362.21, for a total transaction of $25,354,700.00. Following the completion of the sale, the chief executive officer now owns 2,945,366 shares in the company, valued at approximately $1,066,841,018.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Axon Enterprise Stock Down 0.1 %

Shares of NASDAQ AXON opened at $362.00 on Friday. Axon Enterprise, Inc. has a 1 year low of $189.12 and a 1 year high of $378.89. The firm’s 50-day moving average is $323.64 and its 200-day moving average is $307.13. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $27.36 billion, a PE ratio of 105.85, a price-to-earnings-growth ratio of 9.66 and a beta of 0.95.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business’s revenue for the quarter was up 34.5% on a year-over-year basis. During the same period last year, the firm earned $0.80 earnings per share. Equities analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Analysts Set New Price Targets

AXON has been the topic of several research analyst reports. Barclays upped their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Jefferies Financial Group assumed coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target for the company. JMP Securities reissued a “market outperform” rating and issued a $375.00 price objective on shares of Axon Enterprise in a research note on Wednesday, August 7th. Craig Hallum raised their target price on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus price target of $358.08.

Institutional Investors Weigh In On Axon Enterprise

Institutional investors have recently made changes to their positions in the stock. ING Groep NV boosted its holdings in Axon Enterprise by 9.3% during the fourth quarter. ING Groep NV now owns 9,643 shares of the biotechnology company’s stock worth $2,491,000 after buying an additional 821 shares during the last quarter. Avantax Advisory Services Inc. raised its position in shares of Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after acquiring an additional 40 shares during the period. GSA Capital Partners LLP bought a new position in Axon Enterprise during the 1st quarter worth approximately $931,000. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Axon Enterprise by 14.8% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock valued at $53,307,000 after purchasing an additional 22,013 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its stake in Axon Enterprise by 21.7% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock valued at $2,693,000 after purchasing an additional 1,634 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.